Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects*
- 16 July 1995
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 58 (1) , 44-53
- https://doi.org/10.1016/0009-9236(95)90071-3
Abstract
Human pharmacokinetics of an antisense oligodeoxynucleotide phosphorothioate (GEM 91) developed as an anti-human immunodeficiency virus (HIV) agent was carried out in this study. 35S-Labeled GEM 91 was administered to six HIV-infected individuals by means of 2-hour intravenous infusions at a dose of 0.1 mg/kg. Plasma disappearance curves for GEM 91-derived radioactivity could be described by the sum of two exponentials, with half-life values of 0.18 +/- 0.04 and 26.71 +/- 1.67 hours. The radioactivity in plasma was further evaluated by polyacrylamide gel electrophoresis, showing the presence of both intact GEM 91 and lower molecular weight metabolites. Urinary excretion represented the major pathway of elimination, with 49.15% +/- 6.80% of the administered dose excreted within 24 hours and 70.37% +/- 6.72% over 96 hours after dosing. The radioactivity in urine was associated with lower molecular weight metabolites. No drug-related toxicity was observed.Keywords
This publication has 25 references indexed in Scilit:
- Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1Biochemical Pharmacology, 1995
- Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.Proceedings of the National Academy of Sciences, 1991
- Antisense oligonucleotides: gene regulation and chemotherapy of AIDSAdvanced Drug Delivery Reviews, 1991
- The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagentThe Journal of Organic Chemistry, 1990
- Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues.Proceedings of the National Academy of Sciences, 1989
- Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture.Proceedings of the National Academy of Sciences, 1989
- Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.Proceedings of the National Academy of Sciences, 1989
- Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.Proceedings of the National Academy of Sciences, 1988
- Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.Proceedings of the National Academy of Sciences, 1988
- Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.Proceedings of the National Academy of Sciences, 1987